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Abstract 
 
Obesity has reached epidemic proportions in the Western society and is increasing in the 
developing world. It is considered as one of the major contributors to the global burden of 
disability and chronic diseases, including autoimmune, inflammatory and degenerative 
diseases. Research conducted on obesity and its complications over the last two decades 
has transformed the outdated concept of white adipose tissue (WAT) merely serving as an 
energy depot. WAT is now recognized as an active and inflammatory organ capable of 
producing a wide variety of factors known as adipokines. These molecules participate 
through endocrine, paracrine, autocrine, or juxtacrine cross-talk mechanisms in a great 
variety of physiological or pathophysiological processes, regulating food intake, insulin 
sensitivity, immunity, and inflammation. 
Although initially restricted to metabolic activities (regulation of glucose and lipid 
metabolism), adipokines currently represent a new family of proteins that can be considered 
key players in the complex network of soluble mediators involved in the pathophysiology of 
immune/inflammatory diseases. However, the complexity of the adipokine network in the 
pathogenesis and progression of inflammatory diseases has posed, since the beginning, the 
important question of whether it may be possible to target the mechanism(s) by which 
adipokines contribute to disease selectively without suppressing their physiological 
functions.  
Here we explore in depth the most recent findings concerning the involvement of adipokines 
in inflammation and immune responses, in particular in rheumatic, inflammatory and 
degenerative diseases. We also highlight several possible strategies for therapeutic 
development and propose that adipokines and their signalling pathways may represent 
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Abbreviations: 
ADAMTS, a disintegrin and metalloproteinase with thrombospondin motifs; AdipoR, 
adiponectin receptor; AMPK, AMP-activated protein kinase; ATMs, adipose tissue 
macrophages; CAIA, collagen-antibody-induced arthritis; CCL, C-C motif chemokine ligand; 
CIA, collagen-induced arthritis; CPCs, chondrogenic progenitor cells; DCs, dendritic cells; 
DMOAD, disease-modifying OA drug; ELF3, E74-like factor 3; GM-CSF, granulocyte 
macrophage colony-stimulating factor; IPFP, infrapatellar fat pad; LCN2, lipocalin-2; LEPR, 
leptin receptor; MCP-1, monocyte chemoattractant protein-1; NSAIDs, nonsteroidal anti-
inflammatory drugs; OA, osteoarthritis; PGRN, progranulin; PPAR, peroxisome proliferator-
activated receptor; PTP1B, protein tyrosine phosphatase 1B; RA, rheumatoid arthritis; 
RANKL, receptor activator of nuclear factor kappa-B ligand; RASFs, rheumatoid arthritis 
synovial fibroblasts; SF, synovial fluid; SOCS-3, suppressor of cytokine signalling 3; STAT, 
signal transducer and activator of transcription; Th, T helper cells; TIMP, tissue inhibitors of 
metalloproteinases; Treg, T regulatory cells; VCAM, vascular cell adhesion protein; WAT, 
white adipose tissue. 
 
 






























Obesity, the major public health problem in the Western world has reached epidemic 
proportions and continues to rise in developing countries. Being itself one of the major 
contributors to disability, obesity is associated with several chronic autoimmune and 
inflammatory diseases, like type 2 diabetes mellitus, cardiovascular disease, osteoarthritis 
(OA) and rheumatoid arthritis (RA), thus having a high socio-economic impact (Zhang et al., 
2014). For decades, researchers have focused on the identification of risk factors, preventive 
measures, and treatments for obesity. However, public health policies centred on diet and 
physical activity have been largely ineffective. Furthermore, pharmacological approaches 
have not provided any safe and long-term therapies (Zhang et al., 2014). Consequently, it is 
urgent to gain a deeper understanding of the development of obesity-associated pathologies 
and to focus on adipose tissue biology in this context. White adipose tissue (WAT) is now 
recognized as an active endocrine organ besides serving an energy storage tissue, and 
source of adipose tissue-derived factors (adipokines) have been reported as pleiotropic 
molecules that contributed to low-grade systemic inflammation in obese subjects (Tilg and 
Moschen, 2006). Leptin, adiponectin, lipocalin-2, and progranulin are adipokines thought to 
be crucial linkers between obesity and immune system, thus being attractive therapeutic 
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White adipose tissue as a pro-inflammatory tissue in obesity 
WAT is an active endocrine organ consisting of mature and developing adipocytes, 
as well as fibroblasts, endothelial cells and a broad array of immune cells, namely adipose 
tissue macrophages (ATMs), neutrophils, eosinophils, mast cells, T and B cells (Huh et al., 
2014). Thus, WAT is now considered as a bona-fide immunometabolic endocrine organ 
(Vieira-Potter, 2014). 
In WAT of lean individuals, the cross talk between adipocytes and immune cells 
maintains tissue homeostasis. In particular, eosinophils and T regulatory cells (Treg), the 
main resident T cell population, secreted anti-inflammatory cytokines (interleukin (IL)-10 and 
IL-4) that polarize ATMs towards an anti-inflammatory phenotype (i.e. M2 or alternatively 
activated macrophages), thus maintaining a tolerogenic environment (Exley et al., 2014; Huh 
et al., 2014). Moreover, “lean” WAT secretes more adiponectin that enhances the sensitivity 
to insulin. A positive energy balance results in adipocyte expansion, which leads to 
increased leptin secretion and inflammatory cells infiltration. Adipocyte hypoxia, apoptosis, 
and cell stress were able to induce the expression of chemoattractant molecules with the 
consequent recruitment of macrophages, T- and B-cells (Exley et al., 2014; Huh et al., 
2014). T cells become activated, number of T reg cells were reduced and there is a 
macrophage phenotypic switch from M2 to M1, which accumulate around necrotic 
adipocytes forming 'crown-like structures' and producing large amounts of pro-inflammatory 
cytokines, like IL-6 and tumour necrosis factor (TNF)-α (Vieira-Potter, 2014). Additionally, 
obesity is characterized by a dysregulated secretion of WAT adipokines, such as leptin, 
adiponectin, lipocalin-2, and progranulin, which have emerged as crucial regulators of the 
innate and adaptive immune system (Abella et al., 2017b; Scotece et al., 2014; Tilg and 
Moschen, 2006). Altogether, these data revealed WAT as an important contributor to local 
and systemic inflammation in obesity (Figure 1). 
 
The adipokine superfamily 
Adipokines are low molecular weight, pharmacologically active proteins that possess 
pleiotropic activity. Acting in the hypothalamic region as orexigenic and anorexigenic 
hormones, adipokines play a crucial role in energy metabolism by communicating the 
nutrient status of the organism (Al-Suhaimi and Shehzad, 2013). Furthermore, adipokines 
are currently considered as key players in inflammation and immunity, as most of them are 
increased in obesity and contribute to the 'low-grade inflammatory state' associated with 
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Leptin, the forerunner of adipokine family, centrally regulates body weight by linking 
nutritional status and neuroendocrine function. Obese individuals exhibit enhanced 
circulating leptin levels but, due to leptin resistance (unresponsive state to leptin) in the 
hypothalamus, leptin failed to increase energy expenditure and reduce food intake with 
consequent body weight gain (J Conde et al., 2013). Leptin can also stimulate the production 
of pro-inflammatory cytokines and enhance Th1 immune response, thus linking nutrition, 
metabolism and immune homeostasis (Abella et al., 2017b). Adiponectin is an intriguing 
adipokine which is related to insulin sensitivity, anti-atherogenic actions, regulation of 
metabolic homeostasis and modulation of the immune system (Liu and Liu, 2014). In recent 
years, novel adipokines, namely lipocalin-2 and progranulin, have emerged as regulators of 
metabolism and immune function, bridging obesity and inflammatory pathologies that affect 
bones and joints (Abella et al., 2017a; Villalvilla et al., 2016).  
 
Leptin and Leptin Receptors 
Leptin is a 16 kDa non-glycosylated cytokine-like hormone encoded by the LEP gene 
(the human homolog of murine ob gene) located on chromosome 7q31.3 (Green et al., 
1995) and the best-characterized member of adipokine family (Scotece et al., 2014). It is 
mainly produced by adipocytes, and at low levels by skeletal muscle, intestine, gastric 
epithelium, placenta, mammary glands, brain, joint tissues and bone (Scotece et al., 2014). 
In physiological conditions, leptin circulating levels are positively correlated with the WAT 
mass and body mass index, but its synthesis is also modulated by inflammatory factors 
(Conde et al., 2011). This hormone has a central role in body weight homeostasis by 
inducing anorexigenic factors (as cocaine-amphetamine-related transcript) and suppressing 
orexigenic neuropeptides (as neuropeptide Y) on hypothalamus(Zhou and Rui, 2014). 
Therefore, central leptin resistance, caused by impairment of leptin transportation, leptin 
signalling and leptin target neural circuits, is considered the main risk factor for the obesity 
pathogenesis (Zhou and Rui, 2014). Leptin also affects other physiological functions, like 
bone metabolism, inflammation, infection and immune responses. Accordingly, leptin 
receptor is expressed throughout the cells of both innate (natural killer cells, granulocytes, 
monocytes, macrophages, and dendritic cells) and adaptive (B and T cells) immune system 
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Leptin receptors and signalling 
Leptin receptors (LEPR or Ob-R) belong to the class I cytokine receptor family and 
are products of diabetes (db) gene (Münzberg and Morrison, 2015). Alternative splicing of 
the db gene produces at least six isoforms, which possess identical extracellular binding 
domains but differ by the length of the cytoplasmic domain: a long isoform (Ob-Rb), four 
short isoforms (Ob-Ra, Ob-Rc, Ob-Rd, and Ob-Rf) and a soluble isoform (Ob-Re) (Münzberg 
and Morrison, 2015; Zhou and Rui, 2014). Leptin exerts its biological actions through 
activation of the long-form receptor (OB-Rb), which has the full intracellular domain with the 
typical signalling elements of cytokine receptors (Münzberg and Morrison, 2015; Zhou and 
Rui, 2014). This receptor doesn't have intrinsic tyrosine kinase activity but, after leptin 
binding, Ob-Rb-associated Janus-family tyrosine kinase 2 (JAK2) becomes activated by 
auto- or cross-phosphorylation, which are facilitated by the formation of leptin receptor 
homodimers. The cytoplasmic domain of the receptor is then phosphorylated in tyrosine 
residues (Tyr974, Tyr985, Tyr1077, Tyr1138), each one functioning as docking sites for 
cytoplasmic adaptors, like signal transducer and activator of transcription (STAT), 
particularly STAT3 (Zhou and Rui, 2014). Besides the canonical JAK/STAT pathway, LEPR 
also signals via alternative pathways including extracellular signal–regulated kinase 
(ERK)1/2, p38 mitogen-activated protein kinase (MAPK), c-Jun N-terminal kinase (JNK), 
protein kinase C (PKC), SHP2/GRB2 and phosphatidylinositol-4,5-bisphosphate 3-kinase 
(PI3K)/Akt pathways (Scotece et al., 2014; Zhou and Rui, 2014). 
In mouse models, mutations in either ob or db gene result in leptin or LEPR ablation 
and severe obesity. However, in humans, common obesity is often characterized by 
hyperleptinemia and administration of exogenous leptin doesn't result in weight loss, 
indicating an unresponsive state to leptin. Possible mechanisms of leptin resistance include 
decreased levels of cell surface Ob-Rb, up-regulation of negative regulators and down-
regulation of positive regulators. The best-characterized mechanism of leptin resistance in 
the central nervous system is the feedback loop inhibition of leptin signalling by binding of 
suppressor of cytokine signalling 3 (SOCS-3) to phosphorylated tyrosines of Ob-Rb. Protein 
tyrosine phosphatase 1B (PTP1B) also involved acts as negative regulator of leptin 
signalling through JAK2 dephosphorylation (Münzberg and Morrison, 2015; Zhou and Rui, 
2014). In the periphery, leptin is increased in chondrocytes from obese OA patients (Pallu et 
al., 2010) and SOCS-3 expression is lower in cartilage from obese than non-obese 
individuals (Vuolteenaho et al., 2012). Thus, leptin responsiveness should be considered 
when interpreting the leptin effects in peripheral tissues and in the development of leptin-
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Leptin in innate and adaptive immune system 
Leptin has been described as a potent enhancer of the immune system (Abella et al., 
2017b). In innate immunity, leptin augments the cytotoxicity of natural killer (NK) cells, and 
the activation of granulocytes (neutrophils, basophils and eosinophils), macrophages and 
dendritic cells (DCs), thus exacerbating inflammatory responses (Abella et al., 2017b). 
Obese hyperleptinemic individuals have lower NK function compared to lean subjects, likely 
due to leptin resistance (Laue et al., 2015), neutrophils with augmented superoxide release 
and chemotactic activity (Brotfain et al., 2015), and eosinophils with greater adhesion and 
chemotaxis towards eotaxin and CCL5 (Grotta et al., 2013). Leptin-stimulated human 
macrophages have increased M2-phenotype surface markers but were able to secrete M1-
typical cytokines (like TNF-α, IL-6, and IL-1β), indicating that leptin influences ATMs 
phenotype (Acedo et al., 2013). In DCs, leptin modulated their activation, chemoattraction, 
and survival, with possible implications for DCs maturation and migration (Moraes-Vieira et 
al., 2014). Moreover, Toll-like receptors (TLRs), which play a critical role in innate immune 
system, have been described as important players in adipose tissue, obesity-associated 
inflammation and leptin biology (Kim et al., 2012). In particular, leptin-deficient obese mice 
showed increased expression of TLR1-9 and TLR11-13 as well as downstream signalling 
molecules and target cytokines (Kim et al., 2012).  
In the adaptive immune system, leptin augments the proliferation of naïve T cells and 
B cells whereas it decreases Treg cells (Abella et al., 2017b). Accordingly, morbidly obese 
children (congenitally leptin-deficient) had reduced number of circulating CD4+ T cells, and 
impaired T cell proliferation and cytokine release, which were rescued by administration of 
recombinant human leptin (Farooqi et al., 2002), and obese individuals presented reduced 
number of Treg cells (Wagner et al., 2013). Leptin also polarizes Th cells towards a 
proinflammatory (Th1, which secretes interferon (IFN)γ) rather than anti-inflammatory 
phenotype (Th2, which secretes IL-4) (Martín-Romero et al., 2000). In preclinical collagen-
induced arthritis mouse model, the leptin articular injection enhanced Th17 cells in joint 
tissues, with consequent exacerbation of inflammation and early onset of arthritis (Deng et 
al., 2012). Therefore, leptin decreases Treg cell proliferation, whereas it increases Th17 cell 
proliferation and responsiveness, indicating the therapeutic potential of leptin system in 
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Leptin and osteoarthritis 
Osteoarthritis (OA), the most common joint disease, is a degenerative and 
multifactorial pathology triggered by inflammatory and metabolic imbalances affecting the 
entire joint structure (articular cartilage, meniscus, ligaments, bone, and synovium) (Loeser 
et al., 2012). Leptin has been associated with OA and cartilage metabolism, being its levels 
increased in serum, infrapatellar fat pad (IPFP), synovial tissues, and cartilage of OA 
patients compared to healthy individuals (Javier Conde et al., 2013). Additionally, Ob-Rb is 
expressed in chondrocytes and is functional (Figenschau et al., 2001). Recently, a 
microarray analysis associated leptin-induced OA phenotype with the up-regulation of 
inflammatory factors, matrix metalloproteinases (MMPs), growth factors and osteogenic 
genes (Fan et al., 2018). Our group has demonstrated that leptin, in synergy with IL-1β, 
induces the expression of pro-inflammatory factors, namely nitric oxide synthase (NOS)2, 
cyclooxygenase (COX)-2, prostaglandin E2 (PGE2), IL-6, and IL-8 in chondrocytes (Gomez 
et al., 2011). Chondrocyte-synovial fibroblast cross-talk mediates leptin-induced IL-6 
production in OA patients (Pearson et al., 2017). Moreover, leptin modulates the production 
of inflammatory mediators (IL-6, IL-8, and chemokine (C-C motif) ligand 3 (CCL3)) by CD4+ 
T cells in OA patients, but not in healthy subjects (Scotece et al., 2017) hence demonstrating 
new insights into the action of leptin in the immune system and OA pathophysiology. 
Leptin can also promote OA-related joint destruction by directly inducing the 
expression of MMPs (like MMP-1, -2, -3, -9, and -13, A disintegrin and metalloproteinase 
with thrombospondin motifs (ADAMTS)4 and ADAMTS5), while fibroblast growth factor 2 
(FGF2) and proteoglycan were down-regulated (Scotece et al., 2014). Moreover, leptin can 
perpetuate the cartilage-degradation processes via vascular cell adhesion protein (VCAM)-1 
induction in human primary chondrocytes, which attracts leukocytes and monocytes to 
inflamed joints through the action of chemoreceptors (Conde et al., 2012). 
MicroRNAs (miRNAs), small single-stranded non-coding segments of RNA, are 
increasingly recognized as regulatory molecules involved in disease processes, including 
osteoarthritis, inflammation, and obesity. miR-27, which directly targeted the 3'-untranslated 
region (3'-UTR) of leptin, was decreased in OA chondrocytes and injection with miR-27 
lentiviral overexpression vector in preclinical OA rat model resulted in decreased levels of IL-
6 and -8, as well as MMP-9 and -13, thus indicating the protective action of miR-27 in OA, 
possibly by targeting leptin (Zhou et al., 2017). 
Chondrogenic progenitor cells (CPCs) are cartilage seed cells crucial to maintain 
cartilage homeostasis and replace damaged tissue. Leptin reduces CPC migratory ability 
and their chondrogenic potential, and induces CPC senescence and osteogenic 
transformation, thus changing CPC differentiation fate (Zhao et al., 2016). Leptin also 
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regulates bone metabolism via induction of abnormal osteoblast function, which is 
associated with joint destruction in OA patients (Conde et al., 2015).  
Altogether, this evidence indicated a key role of leptin in OA pathophysiology by influencing 
pro-inflammatory status, cartilage catabolic activity, as well as cartilage and bone 
remodelling. 
 
Leptin and rheumatoid arthritis 
Rheumatoid arthritis (RA) is a chronic inflammatory joint disease defined by synovial 
membrane inflammation and hyperplasia (“swelling”), production of autoantibodies ‒ 
autoimmune disease, and destruction of cartilage and bone (“deformity”) (Smolen et al., 
2016). Leptin levels were augmented in RA patients, and its serum and SF levels were 
associated with disease duration,parameters of RA activity and radiographic joint damage 
(Olama et al., 2012; Rho et al., 2009), although there are controversial results and large 
cohort studies are necessary. Leptin-deficient mice demonstrate a less severe antigen-
induced arthritis, decreased levels of TNF-α and IL-1β in knees synovium, a defective cell-
mediated immunity and a shift towards Th-2 cell response (Busso et al., 2002). Moreover, 
reducing leptin levels in RA patients by fasting improves the clinical symptoms of the disease 
(Fraser et al., 1999). Leptin protein mutants with antagonist activity and monoclonal 
antibodies against human leptin receptor or leptin itself are promising therapeutic 
approaches to RA (Tian et al., 2014). Of note, clinical studies evaluating the effect of insulin 
sensitivity modulators (affected by leptin levels), like PPARγ agonists, are ongoing as a new 
potential treatment to improve the inflammatory status and cardiovascular outcome in RA 
patients (Chimenti et al., 2015). Further knowledge on the leptin mechanisms would be 
important for RA treatment. 
Therefore, leptin can be pointed as a linker between immune tolerance, metabolic 
function, and autoimmunity, and approaches directed to leptin signalling could provide future 
innovative therapies for autoimmune disorders like RA. 
 
Adiponectin and Adiponectin Receptors 
Adiponectin, also called GBP28, apM1, Acrp30, or AdipoQ, is a 244-residue protein 
with structural homology to collagen type VIII and X, and complement factor C1q. It is mainly 
synthesized in adipose tissue and exists in several configurations: the globular adiponectin 
(gAPN), the full-length adiponectin (fAPN), the low molecular weight adiponectin (LMW), the 
medium molecular weight adiponectin (MMW), the high molecular weight adiponectin 
(HMW), and the serum albumin bounded LMW form (Alb-LMW) (Liu and Liu, 2014; Sun et 
al., 2009). In morbidly obese patients, circulating adiponectin levels tend to be low, 
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increasing with weight loss and with use of thiazolidinediones (PPAR agonists), which 
enhance insulin sensitivity (Liu and Liu, 2014). Adiponectin acts as an endogenous insulin 
sensitizer by stimulating glucose uptake through its ability to increase fatty acid oxidation 
and to reduce the synthesis of glucose in the liver. Human adiponectin is encoded by 
ADIPOQ gene, which is located on chromosome 3q27 a locus linked with susceptibility to 
diabetes and cardiovascular disease (Liu and Liu, 2014).  
 
Adiponectin receptors and signalling  
Adiponectin acts specifically via two receptors, AdipoR1 predominantly found in 
skeletal muscle and AdipoR2 mainly present in the liver. AdipoRs signalling leads to 
activation of AMP-activated protein kinase (AMPK), PPAR-α, and PPAR-γ (Liu and Liu, 
2014). AMPK activation by adiponectin has been implicated in its insulin-sensitizing activity 
in liver and muscles, while AMPK, Ca2+, and PPAR-α are involved in the regulation of 
glucose and fatty acid metabolism by adiponectin. Ceramide and MAPK signalling pathways 
also mediate the adiponectin action (Liu and Liu, 2014). Increasing evidence reveals the 
importance of adiponectin in inflammation-related pathologies, like cardiovascular disease, 
endothelial dysfunction, type 2 diabetes, metabolic syndrome, OA and RA (Liu and Liu, 
2014), likely due to its ability to modulate innate immune response, as well as B and T cells 
(Luo and Liu, 2016). 
 
Adiponectin in innate and adaptive immune system 
Adiponectin has been recognised as a key regulator of the immune system, playing a 
major role in the progression of inflammatory and metabolic disorders (Luo and Liu, 2016). 
Nevertheless, whether adiponectin behaves as an anti- or pro-inflammatory factor is still a 
matter of intense debate. This adipokine suppresses the differentiation and the classical 
activation of M1 macrophages by down-regulating pro-inflammatory cytokines (TNF-α, 
monocyte chemoattractant protein (MCP)-1, and IL-6), while it promotes M2 macrophage 
proliferation and expression of anti-inflammatory M2 markers (arginase (Arg)-1, Mgl-1, and 
IL-10) (Luo and Liu, 2016). Adiponectin also modulated the eosinophils, neutrophils, NK 
cells, and DCs activity (Luo and Liu, 2016; Tilg and Moschen, 2006) but it remains unclear 
whether adiponectin positively or negatively regulates their function.  These paradoxical dual 
effects might result from different functions of different adiponectin configurations (Sun et al., 
2009). For example, HMW and gAPN but not MMW and LMW adiponectin increased NF-κB 
activity in monocytic cells while gAPN but not fAPN decreased LPS-stimulated ERK1/2 
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In the adaptive immune system, adiponectin activates plasma B cells and stimulate 
the secretion of the B cell-derived peptide PEPITEM, which inhibits the migration of memory 
T cells (Chimen et al., 2015). In T cells, AdipoRs are up-regulated after its activation and 
adiponectin decreased antigen-specific T cell proliferation and cytokines production, via 
enhancement of T cell apoptosis (Procaccini et al., 2013). Adiponectin also enhances Th1 
differentiation and adiponectin-treated DCs significantly induced both Th1 and Th17 
responses in allogenic T cells, contributing to enhanced pro-inflammatory responses 
(Procaccini et al., 2013). A deeper knowledge of adiponectin’s effects on B and T cells and 
its mechanism of action will be important for developing new therapeutic strategies aimed at 
the adiponectin system. 
 
Adiponectin and osteoarthritis 
Adiponectin has been implicated in OA pathophysiology. Serum and plasma 
adiponectin levels are increased in OA patients, compared to healthy individuals, and its 
levels in OA SF were correlated with aggrecan degradation. Moreover, adiponectin could be 
expressed by synovial fibroblasts, IPFP, osteophytes, cartilage and bone tissues within the 
joint (Scotece et al., 2014). Adiponectin has been associated with erosive OA and with OA 
severity assessed radiologically, thus being pointed as a potential OA biomarker (Poonpet, 
2014). However, a recent study reported no association between serum adiponectin levels 
and erosive or non erosive hand OA, while resistin and visfatin were pointed as possible OA 
biomarkers (Fioravanti et al., 2017). 
Spontaneous animal models of OA (STR/Ort mice) present with lower serum 
adiponectin levels than controls. Adiponectin has been reported to have a protective action 
by inhibiting IL-1β-induced MMP-13 expression and to up-regulate tissue inhibitors of 
metalloproteinases (TIMP)-2 production in human chondrocytes (Scotece et al., 2014). 
However, most of the data indicated a pro-inflammatory and catabolic role for adiponectin in 
OA cartilage by increasing the production of NO, IL-6, IL-8, VCAM-1, TIMP-1, MMP-1, -3 
and -13 (Kang et al., 2010; Scotece et al., 2014), which lead to cartilage degradation and OA 
pathogenesis. Furthermore, adiponectin modulates bone metabolism by stimulation of 
human osteoblast proliferation and mineralization, via p38 MAPK signalling pathway and 
bone morphogenetic protein (BMP)-2 (Scotece et al., 2014). Nevertheless, there are 
contradictory results in the literature and further studies are of the utmost importance to 
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Adiponectin and rheumatoid arthritis 
Clinical evidence suggests that adiponectin levels are increased in serum and SF of 
RA patients compared to healthy subjects, and that baseline serum adiponectin levels are 
predictive of RA radiographic progression (Chen et al., 2013; Giles et al., 2009; Rho et al., 
2009). Adiponectin, alone or in combination with IL-1β, induces IL-6, IL-8 and PGE2 
production in RA synovial fibroblasts (RASFs), being the IL-6 production dependent of 
AdipoR1 receptor/AMPK/p38 MAPK/NF-κB signalling pathway (Chen et al., 2013; Scotece et 
al., 2014). Of note, anti-IL-6 receptor monoclonal antibody has been approved in several 
countries for the RA treatment. Adiponectin also increased the production of MMP-1, MMP-
13, and vascular endothelial growth factor (VEGF) in synovial cells, and promoted joint 
inflammation via attraction of immune cells into the synovium and induction of cytokine 
production (Scotece et al., 2014); thus indicating a crucial role of adiponectin in synovitis and 
joint destruction in RA. 
Although in vitro data indicates adiponectin as a potential RA, in in vivo models this 
adipokine exhibits quite different effects. In preclinical collagen-induced arthritis mouse 
model, adiponectin treatment mitigated the severity of arthritis along with a decrease in the 
expression of TNF-α, IL-1β, and MMP-3 in joint tissues (Lee et al., 2008). Future data in 
basic research and clinical observations in large-scale cohort studies are important to 
deeper elucidate the role and mechanisms of adiponectin in inflammatory-related 




Lipocalin-2 (LCN2), also named neutrophil gelatinase-associated lipocalin (NGAL), 
24p3, p25, migration-stimulating factor inhibitor, human neutrophil lipocalin, α-1-
microglobulin-related protein, siderocalin or uterocalin, is a glycoprotein encoded by a gene 
located at the chromosome locus 9q34.11 (Abella et al., 2015). Originally identified in mouse 
kidney cells and human neutrophil granules, adiponectin is also expressed in immune cells, 
liver, spleen, and chondrocytes, although WAT is its major source (Abella et al., 2015). Two 
receptors for LCN2 have been proposed: solute carrier family 22 member 17 (SLC22A17 or 
24p3R) that binds to mouse Lcn2 and the megalin/glycoprotein GP330, a low-density 
lipoprotein receptor that binds human LCN2 protein. LCN2 circulates as a 25 kDa monomer, 
a 46 kDa homodimer and in a covalent complex with MMP-9, thus preventing MMP-9 auto-
degradation (Villalvilla et al., 2016) The members of lipocalin family contain a hydrophobic 
ligand binding pocket, which confers the ability to bind and transport steroids, 
lipopolysaccharides (LPS), fatty acids, iron, and in the case of LCN2, siderophores. LCN2 
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has also been involved in the induction of apoptosis in hematopoietic cells, modulation of 
inflammation and metabolic homeostasis (Abella et al., 2015). Of note, thiazolidinedione 
treatment reverses obesity-induced LCN2 expression (Abella et al., 2015) and there is 
increasing evidence suggesting that LCN2 contributed to obesity-related disorders, like type 
2 diabetes mellitus and non-alcoholic fatty liver disease (Moschen et al., 2017). 
LCN2 binds to enterobactin, a siderophore present in gram-negative bacteria, and 
transport iron into mammalian cells where it is stored. By depleting bacterial iron stores 
necessary for their growth, LCN2 exhibits bacteriostatic effects (Abella et al., 2015), which 
have been implicated in the protection of gastrointestinal tract against various pathogens 
(Moschen et al., 2017). The promoter region of LCN2 contains binding sites for key 
inflammatory transcription factors, like NF-κB, STAT1, STAT3, and C/EBP. Accordingly, 
LCN2 acts as an anti-inflammatory regulator of M1/M2 macrophage polarization via NF-
κB/STAT3 loop activation (Guo et al., 2014). In adaptive immunity, LCN2 induced human 
leukocyte antigen G (HLA-G), a well-known tolerogenic mediator, on CD4+ T cells, and up-
regulated the expansion of Treg cells in healthy subjects (Abella et al., 2015). Taking into 
account the role of LCN2 in the modulation of inflammatory and immune response, future 
studies should investigate the LCN2 therapeutic potential to immunosuppressive therapy 
efficacy, tolerance induction in transplanted patients, and to other inflammatory/immune 
system disorders, such as OA and RA. 
In joint tissues, LCN2 is produced as a mechano-responsive adipokine whose 
expression can be induced by inflammatory mediators. In osteoblasts, the absence of 
mechanical loading stimulates LCN2 expression, likely contributing to bone metabolism via 
stimulation of pro-osteoclastogenic factors, receptor activator of nuclear factor kappa-B 
ligand (RANKL) and IL-6, and inhibition of anti-osteoclastogenic factor osteoprotegerin 
(Abella et al., 2015). The LCN2 expression is also augmented by inflammatory factors TNF-α 
and IL-17 in osteoblasts, whilst in chondrocytes, it is induced by stimulated osteoblast 
conditioned medium, IL-1β, adipokines (leptin and adiponectin), LPS and dexamethasone 
(Villalvilla et al., 2016). Interestingly, NO is able to exert a control on LCN2 expression in 
chondrocytes, suggesting the existence of a feedback loop regulating its expression. 
In OA patients, LCN2 levels are increased in SF and cartilage, where it is involved in 
cartilage degradation via blocking of MMP-9 auto-degradation and reduction of chondrocyte 
proliferation (Abella et al., 2015; Gupta et al., 2007). Recently, glucocorticoids (commonly 
used to treat OA and RA), alone or in combination with IL-1, have been reported to induce 
LCN2 expression through corticoids receptors and PI3K, ERK1/2 and JAK2 pathways in 
mouse chondrogenic cell line (Conde et al., 2017). The transcription factors E74-like factor 3 
(ELF3) and NF-κB were also reported as modulators of LCN2 expression in chondrocytes 
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(Conde et al., 2016). Altogether, these data reveal that LCN2 acts as a sensor of mechanical 
load and inflammatory status of the joint, leading to alterations in subchondral bone, 
cartilage and bone-cartilage crosstalk underlined to OA pathophysiology. Nevertheless, one 
study verified that LCN2 overexpression in mouse cartilage does not cause OA 
pathogenesis and that Lcn2-knockout mice had no alteration in OA cartilage destruction 
induced by destabilization of the medial meniscus (Choi and Chun, 2017). Thus, LCN2 
seems to contribute to OA pathophysiology but it's not sufficient by itself to induce OA 
cartilage destruction in mice. Further studies are necessary to fully elucidate the role of 
LCN2 in human OA development. 
Patients with RA clinically exhibit higher levels of LCN2 in SF than OA patients 
(Katano et al., 2009). Using proteome analysis, it has been demonstrated that granulocyte 
macrophage colony-stimulating factor (GM-CSF) contributed to RA pathophysiology through 
upregulation of LCN2 in neutrophils, followed by induction of TERA, cathepsin D and TG2 in 
synoviocytes, with potential implications in the proliferation of synovial cells and infiltration of 
inflammatory cells into the synovium (Katano et al., 2009). Nevertheless, the action of LCN2 
in RA pathophysiology remains largely unknown. 
 
Progranulin 
Progranulin (PGRN), also known as granulin-epithelin precursor (GEP), proepithelin, 
GP88, PC-cell-derived growth factor (PCDGF), or acrogranin, is a cysteine-rich secreted 
protein encoded by the GRN gene, located on chromosome 17q21.32 (Abella et al., 2017a). 
It is a 68-88kDa secreted glycoprotein that can undergo enzymatic proteolysis into small 
homologous subunits - granulins or epithelins (Wei et al., 2016), and that is produced by a 
wide range of cells, including epithelial cells, macrophages, chondrocytes and also 
adipocytes. Recently identified as an adipokine, PGRN has been implicated in inflammation, 
wound healing, obesity, and rheumatic diseases, like OA and RA, thus having a potential 
role as therapeutic target and biomarker in inflammatory diseases (Abella et al., 2017a). 
PGRN is a key regulator of inflammation, at least in part, due to direct interaction with 
TNF receptors (possessing higher affinity than TNF-α, especially for TNFR2), and 
consequently acting as an antagonist of TNF/TNFR pro-inflammatory signalling (Jian et al., 
2016; Wei et al., 2016). PGRN also bind to death receptor 3 (DR3), which is involved in 
various inflammatory disorders (Jian et al., 2016). Furthermore, PGRN suppressed the 
production of chemokines, like CXCL9 and CXCL10, through the TNFR1 pathway, and 
induced Treg populations and IL-10 production (Jian et al., 2016; Wei et al., 2016). PGRN 
can be degraded by several proteinases, like MMP9, 12, and 14, ADAMTS-7, elastase and 
proteinase-3, originating granulins, which have pro-inflammatory activity and may counteract 
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the anti-inflammatory action of intact PGRN's (Jian et al., 2016). Atsttrin, an engineered 
PGRN-protein, effectively prevents the onset and progression of inflammatory arthritis in 
several preclinical animal models (Liu and Bosch, 2012). Hence, identification of PGRN and 
the discovery of atsttrin as antagonists of TNF-α/TNFR pathway may lead to new therapeutic 
interventions for TNF-α-mediated pathologies, including rheumatic diseases. 
PGRN expression is augmented during chondrocyte differentiation in vitro, as well as 
in cartilage, synovial and IPFP samples from OA patients (Abella et al., 2016). Deficiency of 
PGRN results in OA-like phenotype in aged mice, and both recombinant PGRN and atsttrin 
protect against OA development (Jian et al., 2016). PGRN exhibits anti-inflammatory 
properties in OA by promoting anabolic metabolism via TNFR2, and by inhibiting IL-1β-
mediated catabolic metabolism (suppression of NOS2, COX-2, MMP13 and VCAM-1) 
through TNFR1 binding and blocking of TNF-α mediated activation of NF-κB, thus inhibiting 
MMPS and ADAMTS expression, and cartilage degradation (Abella et al., 2016; Jian et al., 
2016). PGRN also exerts a crucial role in the differentiation and proliferation of 
chondrocytes, and in endochondral ossification of growth plate during development (Feng et 
al., 2010). Intra-articular injection of mesenchymal stem cells that express recombinant 
atsttrin prevents the progression of degenerative changes in a surgically induced preclinical 
OA mouse model (Xia et al., 2015). Moreover, intra-articular injection of etanercept (a fusion-
soluble TNFR2 protein that inhibits TNF-α and has therapeutic activity in RA patients) 
induces more severe joint destruction in preclinical OA mouse model, because it blocks 
PGRN binding to TNFR2 (Jian et al., 2016). Therefore, PGRN directed therapeutic 
approaches seem to be promising for OA treatment. 
In RA patients, circulating and SF levels of PGRN are elevated and are associated 
with disease activity (Cerezo et al., 2015). Furthermore, TNF-α-driven inflammation and 
cartilage destruction are a critical event in the development of RA pathology, and TNF 
biological therapies are considered as the most effective treatments for this autoimmune 
disease (Jian et al., 2016). As TNF/TNFR inhibitor, PGRN-derived atsttrin has been 
extensively studied on RA pathophysiology. In particular, atsttrin administration reduced the 
disease severity in preclinical collagen-induced arthritis (CIA) and collagen-antibody-induced 
arthritis (CAIA) mouse models, being even more effective than PGRN, possibly due to the 
absence of a complete granulin domain with pro-inflammatory activity (Abella et al., 2017a; 
Jian et al., 2016). Interestingly, atsttrin was more effective in reducing inflammation than 
etanercept and demonstrated high stability and was well absorbed when administered 
intraperitoneally in mice (Jian et al., 2016). Regardless the promising therapeutic data of 
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Future Prospects for Therapy 
Great strides have been made in recent years to elucidate the role of adipokines as 
mechanistic drivers of obesity, inflammation, and immunity. This review has summarized the 
increasing evidence of the role of classical adipokines leptin and adiponectin, as well as 
lipocalin-2 and progranulin in obesity-associated inflammatory and autoimmune diseases, 
namely osteoarthritis and rheumatoid arthritis (Figure 2). Current OA drug therapies used in 
clinical practice are mainly based on the use of nonsteroidal anti-inflammatory drugs 
(NSAIDs) and intra-articular administration of corticosteroids, and no disease-modifying OA 
drug (DMOAD) therapies exist with the ability to inhibit structural damage of articular 
cartilage (Glyn-Jones et al., 2015). RA treatment options include anti-TNF-α and anti-IL-1/IL-
1R biologics, but their high cost, and short half-life prompted the development of alternative 
strategies against new therapeutic targets, such as adipokines, multiligand receptor for 
advanced glycation end products (RAGE) as well as inflammatory mediators and signalling 
pathway components (Alghasham and Rasheed, 2014). In fact, the development of 
promising therapeutic approaches targeting adipokine network are already underway. 
Compelling evidence has demonstrated that elevated leptin levels are linked to 
immune system derangements and obesity-associated disorders (Abella et al., 2017b). 
Therefore, control of bioactive levels of leptin, by high-affinity leptin-binding molecules, 
monoclonal humanized antibodies blocking leptin receptor, administration of leptin receptors 
antagonists, or miRNAs targeting leptin, are likely to be feasible therapeutic options (Otvos 
et al., 2011). In the case of adiponectin, only a few protein-based biological modulators have 
been developed due to the extreme insolubility of C-terminal domain and larger peptide 
fragments thereof (Otvos et al., 2014). LCN2 has been implicated in articular cartilage 
degradation (Villalvilla et al., 2016). Silencing RNAs or miRNAs, promotion of protein 
sumoylation and nanoparticle delivery systems for drug administration may be useful 
approaches to regulate LCN2 levels and activity (Meszaros and Malemud, 2012). Moreover, 
the PGRN-derived engineered protein atsttrin was able to prevent inflammation in arthritis 
models (Liu and Bosch, 2012). However, given the pleiotropic action of adipokines, a 
systematic approach to modulate their levels and thus prevent obesity-associated disorders, 
namely osteoarthritis and rheumatoid arthritis, might be, for the moment, unavailable. 
Instead, the local inhibition of adipokines at sites of joint injury or targeting of specific 
receptor isoforms could be a potential viable option. 
Given the role of adipokines in OA and RA pathophysiology, these molecules have 
been singled-out as possible biomarkers for monitoring disease onset and progression, as 
well as the efficiency of therapeutic interventions (Abella et al., 2015; Poonpet, 2014). 
However, further evaluations will be necessary to establish adipokines as OA and RA 
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biomarkers for use in clinical practice. 
Altogether, the data presented and reviewed in this paper proposes adipokines as 
emerging biomarkers and therapeutic targets for immune disorders. However, the adipokine 
network is complex and further insights into the pathophysiological role of adipokines in the 
immune system as well as in the development of obesity-associated disorders will be crucial 
for the development of novel therapeutic approaches. 
 
Nomenclature of Targets and Ligands: 
Key protein targets and ligands in this article are hyperlinked to corresponding entries in 
http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS 
Guide to PHARMACOLOGY (Harding et al., 2018), and are permanently archived in the 
Concise Guide to PHARMACOLOGY 2017/18 (Alexander et al., 2017) 
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Figure 1. White adipose tissue as a pro-inflammatory tissue. In lean adipose tissue, the 
cross-talk between adipocytes and immune resident cells maintains tissue homeostasis. In 
particular, Treg cells secreted anti-inflammatory cytokines (IL10 and IL4) that promotes M2 
macrophage phenotype. Overnutrition results in WAT expansion and adipocyte hypoxia, with 
consequent production of chemoattractants and infiltration of immune cells. B and T cells 
cells become activated, and there is a phenotypic switch from M2 to M1 macrophages, 
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Figure 2. Schematic representation of the adipokines effects on inflammatory 
diseases  
 
 
 
